X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3355) 3355
Publication (352) 352
Book Review (33) 33
Book Chapter (17) 17
Magazine Article (11) 11
Conference Proceeding (8) 8
Government Document (3) 3
Trade Publication Article (3) 3
Data Set (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Paper (1) 1
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sofosbuvir (2337) 2337
index medicus (2069) 2069
humans (1970) 1970
hepatitis c (1596) 1596
hepatitis c virus (1392) 1392
antiviral agents - therapeutic use (1225) 1225
ribavirin (1216) 1216
gastroenterology & hepatology (1121) 1121
hepatitis c, chronic - drug therapy (1106) 1106
male (1012) 1012
female (932) 932
middle aged (888) 888
hepatitis (884) 884
interferon (795) 795
hepacivirus - genetics (766) 766
genotype (742) 742
ledipasvir (716) 716
hcv (704) 704
drug therapy, combination (703) 703
antiviral agents (688) 688
treatment outcome (671) 671
infection (630) 630
cirrhosis (578) 578
hepatitis c - drug therapy (566) 566
virus-infection (558) 558
adult (551) 551
aged (531) 531
health aspects (531) 531
infectious diseases (517) 517
therapy (513) 513
sofosbuvir - therapeutic use (490) 490
hepacivirus - drug effects (483) 483
pharmacology & pharmacy (478) 478
liver (467) 467
antiviral agents - administration & dosage (450) 450
ribavirin - therapeutic use (450) 450
sustained virological response (439) 439
patients (430) 430
care and treatment (420) 420
infections (414) 414
antiviral agents - adverse effects (407) 407
genotype 1 infection (407) 407
drug therapy (403) 403
analysis (402) 402
daclatasvir (400) 400
hepatitis c, chronic - virology (389) 389
liver cirrhosis (363) 363
virology (342) 342
genotype 1 (340) 340
uridine monophosphate - analogs & derivatives (340) 340
sustained virologic response (336) 336
direct-acting antivirals (327) 327
simeprevir (321) 321
viruses (314) 314
genotype & phenotype (309) 309
treatment-naive patients (305) 305
transplantation (295) 295
virus diseases (295) 295
biological response modifiers (293) 293
liver transplantation (282) 282
hepatitis-c virus (268) 268
medicine, general & internal (264) 264
hepatitis c, chronic - complications (258) 258
genotypes (256) 256
genetic aspects (254) 254
pegylated interferon (252) 252
immunology (247) 247
abridged index medicus (244) 244
uridine monophosphate - therapeutic use (243) 243
sofosbuvir - administration & dosage (241) 241
treatment-naive (241) 241
efficacy (240) 240
hepatology (239) 239
hcv infection (236) 236
open-label (233) 233
gastroenterology and hepatology (230) 230
plus ribavirin (227) 227
microbiology (224) 224
united-states (222) 222
antiviral agents - pharmacology (216) 216
sofosbuvir plus ribavirin (215) 215
prevalence (214) 214
medical research (213) 213
liver diseases (212) 212
antiviral therapy (211) 211
hepatitis c - virology (211) 211
retrospective studies (210) 210
ribavirin - administration & dosage (209) 209
velpatasvir (208) 208
hepacivirus (206) 206
sofosbuvir - adverse effects (201) 201
benzimidazoles - therapeutic use (199) 199
combination (198) 198
recurrence (197) 197
chronic hepatitis-c (196) 196
safety (195) 195
young adult (195) 195
research (194) 194
telaprevir (192) 192
viral load (191) 191
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3208) 3208
Korean (59) 59
German (49) 49
Spanish (28) 28
French (14) 14
Hungarian (10) 10
Chinese (6) 6
Czech (5) 5
Japanese (5) 5
Russian (2) 2
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medicine, ISSN 0025-7974, 2017, Volume 96, Issue 6, p. e6128
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 153, Issue 1, pp. 113 - 122
Background & Aims Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment... 
Gastroenterology and Hepatology | Direct-Acting Antiviral Agent | Shortened Duration Therapy | Clinical Trial | Comparison | PROTEASE INHIBITOR GS-9857 | SIMEPREVIR PLUS SOFOSBUVIR | COMBINATION | CHALLENGES | GENOTYPE 1 | TREATMENT-NAIVE | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | DIRECT-ACTING ANTIVIRALS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Middle Aged | Male | Carbamates - administration & dosage | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Drug Therapy, Combination | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Macrocyclic Compounds - therapeutic use | Sofosbuvir - administration & dosage | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Medical colleges | Care and treatment | Protease inhibitors | Proteases | Transplantation of organs, tissues, etc | Product development | Hepatitis C virus | Hepatitis C | Health aspects | Analysis
Journal Article
Journal Article
Haemophilia, ISSN 1351-8216, 03/2017, Volume 23, Issue 2, pp. 198 - 206
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1405 - 1411
Background. Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment... 
Hepatitis C virus | DAA | Drug use | PWID | Opioid substitution therapy | UNITED-STATES | INFECTIOUS DISEASES | METAANALYSIS | SOFOSBUVIR | MICROBIOLOGY | IMMUNOLOGY | LEDIPASVIR | HEPATITIS-C VIRUS | REINFECTION | hepatitis C virus | drug use | opioid substitution therapy | INJECT DRUGS | PEOPLE | USERS | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Drug Users | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Opiate Substitution Treatment | Retrospective Studies | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Data Interpretation, Statistical | Enzyme-Linked Immunosorbent Assay | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Sustained Virologic Response | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Treatment outcome | Safety and security measures | Analysis | Dosage and administration | Hepatitis C | Drug therapy | Ribavirin
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2016, Volume 63, Issue 11, pp. 1479 - 1481
Journal Article
Journal Article
Liver Transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or... 
SURGERY | INTERFERON-ALPHA-2B | ANTIVIRAL THERAPY | RIBAVIRIN | COMBINATION | VIROLOGICAL RESPONSE | HCV INFECTION | TRANSPLANTATION | GENOTYPE 1 | PLUS SOFOSBUVIR | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | COMPASSIONATE USE | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Infectious Medicine | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Infektionsmedicin
Journal Article